Immunotherapy is a treatment strategy that has demonstrated survival benefit for metastatic melanoma. Ipilimumab and nivolumab are examples of immunotherapy, in which monoclonal antibodies antagonize cytotoxic T-lymphocyte-associated protein 4 and programmed death-ligand 1 receptors, respectively, resulting in upregulation of the host immune response to cancer cells. There is increasing recognition of immune-mediated adverse events associated with immune therapies in patients with cancer. We present a case report of a patient who developed Miller Fisher syndrome associated with these therapies for metastatic melanoma along with a discussion of its management.
HaoCTianJLiuHLiFNiuHZhuB. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(26):e7325.
2.
WeberJSDummerRde PrilVLebbeCHodiFS. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer. 2013;119(9):1675–1682.
3.
SpainLDiemSLarkinJ. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.
4.
FisherM. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Engl J Med. 1956;255(2):57–65.
5.
JacobsBCEndtzHPvan der MecheFGHazenbergMPde KlerkMAvan DoornPA. Humoral immune response against Campylobacter jejuni lipopolysaccharides in Guillain-Barre and Miller Fisher syndrome. J Neuroimmunol. 1997;79(1):62–68.
6.
ShahrizailaNYukiN. Antiganglioside antibodies in Guillain-Barre syndrome and its related conditions. Expert Rev Neurother. 2011;11(9):1305–1313.
7.
JohnsonDBFriedmanDLBerryE. Survivorship in immune therapy: assessing chronic immune toxicities, health outcomes, and functional status among long-term ipilimumab survivors at a single referral center. Cancer Immunol Res. 2015;3(5):464–469.
8.
LiaoBShroffSKamiya-MatsuokaCTummalaS. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neurooncology. 2014;16(4):589–593.
9.
MaurMTomaselloCFrassoldatiADieciMVBarbieriEConteP. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 2012;30(6): e76–e78.
SchneiderbauerRSchneiderbauerMWickWEnkAHHaenssleHAHasselJC. PD-1 antibody-induced Guillain-Barre syndrome in a patient with metastatic melanoma. Acta Derm Venereol. 2017;97(3):395–396.
12.
SuzukiSIshikawaNKonoedaF. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017;89(11):1127–1134.
13.
MakariousDHorwoodKCowardJIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128–136.
14.
Gaudy-MarquesteCMonestierSFranquesJCantaisERichardMAGrobJJ. A severe case of ipilimumab-induced Guillain-Barre syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother. 2013;36(1):77–78.
